Protecting the family to protect the child: Vaccination strategy guided by RSV transmission dynamics

Journal of Infectious Diseases

Volumn 209, Issue 11, 2014, Pages 1679-1681

  Graham, Barney S ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVE IMMUNIZATION; DISEASE SEVERITY; HOUSEHOLD; HUMAN; INFECTION PREVENTION; INFECTION RISK; NONHUMAN; NOTE; PRIORITY JOURNAL; PUBLIC HEALTH; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; STRATEGIC PLANNING; VACCINE PRODUCTION; VIRUS DETECTION; VIRUS NEUTRALIZATION; VIRUS TRANSMISSION;

FEMALE; HUMANS; MALE; NASOPHARYNX; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES;

EID: 84900537298     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu075     Document Type: Note

References (11)

1. Lozano R, Ortblad KF, Lopez AD, Murray CJ. Mortality from HIV in the Global Burden of Disease study: authors' reply. Lancet 2013; 381: 991-2.
2. Falsey AR. Editorial commentary: respiratory syncytial virus: a global pathogen in an aging world. Clin Infect Dis 2013; 57: 1078-80.
3. Lee N, Lui GC,Wong KT, et al. High morbidity and mortality in adults hospitalized for respiratory syncytial virus infections. Clin Infect Dis 2013; 57: 1069-77.
4. Munywoki PK, Koech DC, Agoti CN, et al. The source of respiratory syncytial virus infection in infants: a household cohort study in Rural Kenya. J Infect Dis 2014; 209: 1685-92.
5. Hall CB, Geiman JM, Biggar R, Kotok DI, Hogan PM, Douglas GR Jr. Respiratory syncytial virus infections within families. N Engl J Med 1976; 294: 414-9.
6. Malloy AM, Falsey AR, Ruckwardt TJ. Consequences of immature and senescent immune responses for infection with respiratory syncytial virus. Curr Top Microbiol Immunol 2013; 372: 211-31.
7. Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969; 89: 422-34.
8. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact- RSV Study Group. Pediatrics 1998; 102: 531-7.
9. Blanken MO, Rovers MM, Bont L. Respiratory syncytial virus and recurrent wheeze. N Engl J Med 2013; 369: 782-3.
10. Preziosi MP, HalloranME. Effects of pertussis vaccination on transmission: vaccine efficacy for infectiousness. Vaccine 2003; 21: 1853-61.
11. Baguelin M, Flasche S, Camacho A, Demiris N, Miller E, Edmunds WJ. Assessing optimal target populations for influenza vaccination programmes: an evidence synthesis and modelling study. PLoS Med 2013; 10: e1001527.